· GeneSprout · In The News
JAMA Calls for a Rethink of Pediatric Genetic Care — GeneSprout Is Already Answering
A new JAMA viewpoint argues that rare genetic diseases are a core health system problem, not a niche concern. Here's what the research says — and how GeneSprout is helping families, providers, and health plans act on it.
A viewpoint published in JAMA in March 2026 makes the case plainly: rare genetic diseases are not a niche concern. Collectively, they represent one of the largest and most underrecognized sources of pediatric illness, hospitalization, and health care spending in the United States — and the systems designed to address them haven’t kept pace with what the science now makes possible.
The article, authored by Harry Ostrer, MD of Albert Einstein College of Medicine, calls for a fundamental rethink of how pediatric genetic care is delivered, coordinated, and supported across the entire health ecosystem.
What the research found
The numbers are striking. Genetic disorders affect an estimated 5% to 10% of all children and account for roughly one-third of pediatric hospital discharges and nearly half of all inpatient charges. An estimated 10% to 25% of neonatal intensive care unit admissions involve an undiagnosed genetic condition.
Despite this, the path to diagnosis remains deeply flawed. Diagnostic odysseys — the lengthy, often exhausting search for a genetic diagnosis — commonly last four to six years. The causes are structural: limited recognition of early warning signs, delayed referrals, fragmented testing, and unequal access to specialist expertise.
The science, meanwhile, has moved forward dramatically. Whole exome and genome sequencing now achieve diagnostic yields approaching 50% for children with congenital anomalies, neurodevelopmental disorders, and sensory deficits. Genotype-informed therapies — including enzyme replacement, gene therapy, and cell-based treatments — are transforming what is possible for children who receive a timely diagnosis. The gap between what the science can do and what health systems currently deliver is widening.
Dr. Ostrer’s conclusion is direct: improving outcomes for children with genetic disease is not primarily a technology problem. It is a structural one. And solving it requires coordinated action across families, clinicians, health systems, payers, and laboratories.
Where GeneSprout fits
GeneSprout was built precisely for this gap — and for every stakeholder the JAMA article identifies.
For families, the barrier to early genetic insight has historically been access: access to the right test, the right interpretation, and the right support after results arrive. GeneSprout brings whole exome and whole genome sequencing directly to families through a simple at-home cheek swab, with plain-language reports and a condition navigation team that supports families from results through the establishment of a care team and beyond. The diagnostic odyssey doesn’t have to last years. Learn more about GeneSprout for families →
For health plans and payers, the JAMA article makes the value-based case clearly: early diagnosis reduces unnecessary testing, avoidable hospitalizations, and the cumulative cost of delayed intervention. Dr. Ostrer calls on payers specifically to “redefine medical necessity to include genomic sequencing” and shift toward reimbursement models that reward early diagnosis and personalized medicine. GeneSprout is a ready partner for health plans seeking to expand proactive pediatric genetic screening for their members. Learn more about GeneSprout for health plans →
For providers, the article highlights the critical role of primary care clinicians in earlier phenotypic recognition — and the need for better decision support, clearer referral pathways, and collaborative care models that bring genetics closer to the front line of pediatric practice. GeneSprout works alongside pediatric providers, delivering results designed to be shared with care teams and supporting the coordination that complex findings require. Learn more about GeneSprout for providers →
The moment we’re in
The JAMA viewpoint frames the current moment as a mandate — not just an opportunity. The therapies exist. The sequencing technology exists. What’s needed now is the infrastructure, the access, and the will to act before children fall further behind.
GeneSprout’s mission is to make that action possible for every family, regardless of whether they have a medical background, a specialist in their network, or a health plan that covers sequencing. Knowing tomorrow starts today — and today, the science is ready.
Ostrer H. When Rare Is Common — Rethinking Pediatric Genetic Care. JAMA. Published online March 25, 2026. doi:10.1001/jama.2026.2072
This post summarizes a published viewpoint for informational purposes. It does not constitute medical advice.